<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIPHENOXYLATE HCL AND ATROPINE SULFATE - diphenoxylate  hydrochloride and atropine sulfate tablet </strong><br>Stat Rx USA<br></p></div>
<h1>Diphenoxylate Hydrochloride and Atropine Sulfate (Diphenoxylate Hydrochloride and Atropine Sulfate)  tablet  </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<a href="#section-"></a>DESCRIPTION<p class="First">Each tablet, for oral administration, contains:</p>
<p>Diphenoxylate Hydrochloride USP . . . . . . . . . . . 2.5 mg</p>
<p>Atropine Sulfate USP . . . . . . . . . . . . . . . . . . . . . 0.025 mg</p>
<p>In addition, each tablet, contains the following inactive ingredients: 
confectioner’s sugar, corn starch, lactose monohydrate, magnesium stearate and 
sodium starch glycolate.</p>
<p>Diphenoxylate hydrochloride, an antidiarrheal, is ethyl 
1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride and has 
the following structural formula:</p>
<p>                                                                                                                        <img alt="Structure Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542b6ceb-7ad4-4d0d-b604-79bd1f567d79&amp;name=DiphAtro_struct1.jpg"></p>
<p><br></p>
<p>C<span class="Sub">30</span>H<span class="Sub">32</span>N<span class="Sub">2</span>O<span class="Sub">2</span>•HCl M.W. 489.06</p>
<p>Atropine sulfate, an anticholinergic, is Benzeneacetic 
acid,-(hydroxymethyl)-8-methyl-8-azabicyclol [3.2.1] oct-3-yl ester, <span class="Italics">endo</span>-±, sulfate(2:1) (salt), monohydrate and has the 
following structural formula:<br></p>
<br><p>                                                                                            <img alt="Structure Image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542b6ceb-7ad4-4d0d-b604-79bd1f567d79&amp;name=DiphAtro_struct2.jpg">                                                                                                                                                                                                                                                                                                           </p>
<p>C<span class="Sub">17</span>H<span class="Sub">23</span>NO<span class="Sub">3</span>)<span class="Sub">2</span>•H<span class="Sub">2</span>SO<span class="Sub">4</span>•H20 M.W. 694.85</p>
<p>A subtherapeutic amount of atropine sulfate is present to discourage 
deliberate overdosage.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<a href="#section-"></a><span class="Bold">CLINICAL PHARMACOLOGY<br><br></span><p class="First">Diphenoxylate is rapidly and extensively metabolized in man by 
ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active 
and the major metabolite in the blood. After a 5 mg oral dose of carbon-14 
labeled diphenoxylate hydrochloride in ethanolic solution was given to three 
healthy volunteers, an average of 14% of the drug plus its metabolites was 
excreted in the urine and 49% in the feces over a four-day period. Urinary 
excretion of the unmetabolized drug constituted less than 1% of the dose, and 
diphenoxylic acid plus its glucuronide conjugate constituted about 6% of the 
dose. In a sixteen-subject cross-over bioavailability study, a linear 
relationship in the dose range of 2.5 to 10 mg was found between the dose of 
diphenoxylate hydrochloride (given as diphenoxylate HCl and atropine sulfate 
oral solution) and the peak plasma concentration, the area under the plasma 
concentration-time curve, and the amount of diphenoxylic acid excreted in the 
urine. In the same study the bioavailability of the tablet compared with an 
equal dose of the liquid was approximately 90%. The average peak plasma 
concentration of the diphenoxylic acid following ingestion of four 2.5 mg 
tablets was 163 ng/mL at about 2 hours, and the elimination half-life of 
diphenoxylic acid was approximately 12 to 14 hours.</p>
<p>In dogs, diphenoxylate hydrochloride has a direct effect on circular smooth 
muscle of the bowel, that conceivably results in segmentation and prolongation 
of gastrointestinal transit time. The clinical antidiarrheal action of 
diphenoxylate hydrochloride may thus be a consequence of enhanced segmentation 
that allows increased contact of the intraluminal contents with the intestinal 
mucosa.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<a href="http://"></a><span class="Bold">INDICATIONS AND USAGE</span><br><br><p class="First">Diphenoxylate hydrochloride and atropine sulfate tablets are 
effective as adjunctive therapy in the management of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<br><a href="http://"></a><span class="Bold">CONTRAINDICATIONS</span><p class="First">Diphenoxylate HCl and atropine sulfate tablets are 
contraindicated in patients with:</p>
<ol>
<li>known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diphenoxylate or atropine. 
</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">obstructive jaundice</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span> or 
enterotoxin-producing bacteria </li>
</ol>
<br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<a href="http://"></a><span class="Bold">WARNINGS</span><p class="First">THIS IS <span class="Italics">NOT</span> AN INNOCUOUS DRUG AND 
DOSAGE RECOMMENDATIONS SHOULD BE STRICTLY ADHERED TO, ESPECIALLY IN CHILDREN. 
DIPHENOXYLATE HCl AND ATROPINE SULFATE IS NOT RECOMMENDED FOR CHILDREN UNDER 2 
YEARS OF AGE. OVERDOSAGE MAY RESULT IN SEVERE <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span>, 
POSSIBLY LEADING TO PERMANENT <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">BRAIN DAMAGE</span> OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> (SEE <span class="Bold">OVERDOSAGE</span>). THEREFORE, KEEP THIS MEDICATION OUT OF THE REACH 
OF CHILDREN.</p>
<p>THE USE OF DIPHENOXYLATE HCl AND ATROPINE SULFATE SHOULD BE ACCOMPANIED BY 
APPROPRIATE FLUID AND ELECTROLYTE THERAPY, WHEN INDICATED. IF SEVERE <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">DEHYDRATION</span> 
OR <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE IMBALANCE</span> IS PRESENT, THIS PRODUCT SHOULD BE WITHHELD UNTIL 
APPROPRIATE CORRECTIVE THERAPY HAS BEEN INITIATED. DRUG-INDUCED INHIBITION OF 
PERISTALSIS MAY RESULT IN <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span> IN THE INTESTINE, WHICH MAY FURTHER 
AGGRAVATE <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">DEHYDRATION</span> AND <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE IMBALANCE</span>. DIPHENOXYLATE HCl AND ATROPINE 
SULFATE SHOULD BE USED WITH SPECIAL CAUTION IN YOUNG CHILDREN BECAUSE THIS AGE 
GROUP MAY BE PREDISPOSED TO DELAYED DIPHENOXYLATE TOXICITY AND BECAUSE OF THE 
GREATER VARIABILITY OF RESPONSE IN THIS AGE GROUP.</p>
<p>Antiperistaltic agents may prolong and/or worsen <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with 
organisms that penetrate the intestinal mucosa (toxigenic <span class="Italics">E. 
Coli, <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>, Shigella</span>), and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span> 
associated with broad-spectrum antibiotics. Antipersistaltic agents should not 
be used in these conditions.</p>
<p>In some patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span>, agents that inhibit 
intestinal motility or prolong intestinal transit time have been reported to 
induce toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>. Consequently, patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span> 
should be carefully observed and diphenoxylate HCl and atropine sulfate therapy 
should be discontinued promptly if abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> occurs or if other 
untoward symptoms develop.</p>
<p>Since the chemical structure of diphenoxylate hydrochloride is similar to 
that of meperidine hydrochloride, the concurrent use of this product with 
monoamine oxidase (MAO) inhibitors may, in theory, precipitate hypertensive 
crisis.</p>
<p>This product should be used with extreme caution in patients with advanced 
hepatorenal disease and in all patients with abnormal liver function since 
<span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> may be precipitated. Diphenoxylate hydrochloride may potentiate the 
action of barbiturates, tranquilizers, and alcohol. Therefore, the patient 
should be closely observed when any of these are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<a href="#section-"></a><span class="Bold">PRECAUTIONS<br><br></span><a href="#section-"></a><a href="#section-"></a><span class="Bold">General</span><br><br><p class="First">Since a subtherapeutic dose of atropine has been added to the 
diphenoxylate hydrochloride, consideration should be given to the precautions 
relating to the use of atropine. In children, diphenoxylate HCl and atropine 
sulfate should be used with caution since signs of atropinism may occur even 
with recommended doses, particularly in patients with Down’s syndrome.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7"></a><p></p>
<a href="#section-"></a><span class="Bold">Information for Patients</span><br><br><p class="First">INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE 
RECOMMENDED DOSAGE AND TO KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN AND IN 
A CHILD-RESISTANT CONTAINER. INFORM THE PATIENT OF THE CONSEQUENCES OF 
OVERDOSAGE, INCLUDING SEVERE <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span>, POSSIBLY LEADING 
TO PERMANENT <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">BRAIN DAMAGE</span> OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>. Diphenoxylate HCl and atropine sulfate may 
produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The patient should be cautioned regarding 
activities requiring mental alertness, such as driving or operating dangerous 
machinery. Potentiation of the action of alcohol, barbiturates, and 
tranquilizers with concomitant use of this product should be explained to the 
patient. The physician should also provide the patient with other information in 
this labeling, as appropriate.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Drug Interactions</span><br><br><p>Known drug interactions include barbiturates, tranquilizers, and 
alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors 
(see <span class="Bold">WARNINGS</span>).</p>
<p>In studies with male rats, diphenoxylate hydrochloride was found to inhibit 
the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, 
diphenoxylate has the potential to prolong the biological half-lives of drugs 
for which the rate of elimination is dependent on the microsomal drug 
metabolizing enzyme system.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Carcinogenesis, Mutagenesis, and Impairment of 
Fertility</span><br><br><p>No long-term study in animals has been performed to evaluate 
carcinogenic potential. Diphenoxylate hydrochloride was administered to male and 
female rats in their diets to provide dose levels of 4 and 20 mg/kg/day 
throughout a three-litter reproduction study. At 50 times the human dose (20 
mg/kg/day), female <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reduced and there was a marked effect on 
fertility as only 4 of 27 females became pregnant in three test breedings. The 
relevance of this finding to usage of diphenoxylate HCl and atropine sulfate in 
humans is unknown.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Pregnancy<br><br></span><a href="#section-"></a><a href="#section-"></a>Pregnancy Category C<p>Diphenoxylate hydrochloride has been shown to have an effect on 
fertility in rats when given in doses 50 times the human dose (see above 
discussion). Other findings in this study include a decrease in maternal weight 
gain of 30% at 20 mg/kg/day and of 10% at 4 mg/kg/day. At 10 times the human 
dose (4 mg/kg/day), average litter size was slightly reduced.</p>
<p>Teratology studies were conducted in rats, rabbits, and mice with 
diphenoxylate hydrochloride at oral doses of 0.4 to 20 mg/kg/day. Due to 
experimental design and small numbers of litters, embryotoxic, fetotoxic, or 
teratogenic effects cannot be adequately assessed. However, examination of the 
available fetuses did not reveal any indication of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>There are no adequate and well-controlled studies in pregnant women. This 
product should be used during pregnancy only if the anticipated benefit 
justifies the potential risk to the fetus.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Nursing Mothers</span><br><br><p>Caution should be exercised when this product is administered to 
a nursing woman, since the physicochemical characteristics of the major 
metabolite, diphenoxylic acid, are such that it may be excreted in breast milk 
and since it is known that atropine is excreted in breast milk.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Pediatric Use</span><br><br><p>Diphenoxylate HCl and atropine sulfate may be used as an adjunct 
to the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> but should be accompanied by appropriate fluid and 
electrolyte therapy, if needed. DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE 
IS NOT RECOMMENDED FOR PEDIATRIC PATIENTS UNDER 2 YEARS OF AGE. Diphenoxylate 
HCl and atropine sulfate should be used with special caution in young children 
because of the greater variability of response in this age group. See WARNINGS 
and DOSAGE AND ADMINISTRATION. In case of accidental ingestion by children, see 
OVERDOSAGE for recommended treatment.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<a href="#section-"></a><span class="Bold">ADVERSE REACTIONS</span><p class="First">At therapeutic doses, the following have been reported; they are 
listed in decreasing order of severity, but not of frequency:</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Nervous system</span><p><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness of extremities</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, 
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Allergic</span><p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the 
gums, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Gastrointestinal system</span><p>Toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> The following atropine sulfate effects are listed 
in decreasing order of severity, but not of frequency: <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, dryness of the skin and mucous 
membranes. These effects may occur, especially in children.</p>
<p>THIS MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE 
REACH OF CHILDREN SINCE AN OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">COMA</span>, POSSIBLY LEADING TO PERMANENT <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">BRAIN DAMAGE</span> OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<a href="#section-"></a><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span><br><br></span><a href="#section-"></a><a href="#section-"></a><span class="Bold">Controlled Substance</span><p class="First">Diphenoxylate HCl and atropine sulfate tablets are classified as 
a Schedule V controlled substance by federal regulation. Diphenoxylate 
hydrochloride is chemically related to the narcotic analgesic meperidine.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span><p>In doses used for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, whether acute or 
chronic, diphenoxylate has not produced addiction.</p>
<p>Diphenoxylate hydrochloride is devoid of morphine-like subjective effects at 
therapeutic doses. At high doses it exhibits codeine-like subjective effects. 
The dose which produces antidiarrheal action is widely separated from the dose 
which causes central nervous system effects. The insolubility of diphenoxylate 
hydrochloride in commonly available aqueous media precludes intravenous 
self-administration. A dose of 100 to 300 mg/day, which is equivalent to 40 to 
120 tablets, administered to humans for 40 to 70 days, produced opiate 
withdrawal symptoms. Since addiction to diphenoxylate hydrochloride is possible 
at high doses, the recommended dosage should not be exceeded.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<a href="#section-"></a><span class="Bold">OVERDOSAGE</span><br><br><p class="First">RECOMMENDED DOSAGE SCHEDULES SHOULD BE STRICTLY FOLLOWED. THIS 
MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE REACH OF 
CHILDREN, SINCE AN OVERDOSAGE MAY RESULT IN SEVERE, EVEN FATAL, RESPIRATORY 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span>.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Diagnosis</span><br><br><p>Initial signs of overdosage may include dryness of the skin and 
mucous membranes, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, and 
tachychardia followed by <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, hypotonic reflexes, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, 
pinpoint pupils, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> may be 
evidenced as late as 30 hours after ingestion and may recur in spite of an 
initial response to narcotic antagonists. TREAT ALL POSSIBLE DIPHENOXYLATE HCl 
AND ATROPINE SULFATE OVERDOSAGES AS SERIOUS AND MAINTAIN MEDICAL OBSERVATION FOR 
AT LEAST 48 HOURS, PREFERABLY UNDER CONTINUOUS HOSPITAL CARE.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Treatment</span><br><br><p>In the event of overdosage, induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric 
lavage, establishment of a patent airway, and possibly mechanically assisted 
respiration are advised. <span class="Italics">In vitro</span> and animal studies 
indicate that activated charcoal may significantly decrease the bioavailability 
of diphenoxylate. In noncomatose patients, a slurry of 100 g of activated 
charcoal can be administered immediately after the induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or 
gastric lavage.</p>
<p>A pure narcotic antagonist (e.g., naloxone) should be used in the treatment 
of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by diphenoxylate HCl and atropine sulfate. When 
a narcotic antagonist is administered intravenously, the onset of action is 
generally apparent within two minutes. It may also be administered 
subcutaneously or intramuscularly, providing a slightly less rapid onset of 
action but a more prolonged effect.</p>
<p>To counteract <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by diphenoxylate/atropine 
overdosage, the following dosage schedule for the narcotic antagonist naloxone 
hydrochloride should be followed:</p>
<a href="#section-"></a><a href="#section-"></a>Adult dosage<p>An initial dose of 0.4 mg to 2 mg of naloxone hydrochloride may 
be administered intravenously. If the desired degree of counteraction and 
improvement in respiratory functions is not obtained, it may be repeated at 2 to 
3 minute intervals. If no response is observed after 10 mg of naloxone 
hydrochloride has been administered, the diagnosis of narcotic-induced or 
partial narcotic-induced toxicity should be questioned. Intramuscular or 
subcutaneous administration may be necessary if the intravenous route is not 
available.</p>
<a href="#section-"></a><a href="#section-"></a>Children<p>The usual initial dose in children is 0.01 mg/kg body weight 
given I.V. If this dose does not result in the desired degree of clinical 
improvement, a subsequent dose of 0.1 mg/kg body weight may be administered. If 
an I.V. route of administration is not available, naloxone hydrochloride may be 
administered I.M. or S.C. in divided doses. If necessary, naloxone hydrochloride 
can be diluted with sterile water for injection.</p>
<p>Following initial improvement of respiratory function, repeated doses of 
naloxone hydrochloride may be required to counteract recurrent respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Supplemental intramuscular doses of naloxone hydrochloride may be 
utilized to produce a longer-lasting effect.</p>
<p>Since the duration of action of diphenoxylate hydrochloride, is longer than 
that of naloxone hydrochloride, improvement of respiration following 
administration may be followed by recurrent <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. 
Consequently, continuous observation is necessary until the effect of 
diphenoxylate hydrochloride on respiration has passed. This effect may persist 
for many hours. The period of observation should extend over at least 48 hours, 
preferably under continuous hospital care. Although signs of overdosage and 
<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may not be evident soon after ingestion of diphenoxylate 
hydrochloride, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur from 12 to 30 hours later.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<a href="#section-"></a><span class="Bold">DOSAGE AND ADMINISTRATION</span><p class="First">DO NOT EXCEED RECOMMENDED DOSAGE.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a>Adults<p>The recommended initial dosage is two tablets four times daily 
(20 mg per day). Most patients will require this dosage until initial control 
has been achieved, after which the dosage may be reduced to meet individual 
requirements. Control may often be maintained with as little as 5 mg (two 
tablets) daily.</p>
<p>Clinical improvement of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">acute diarrhea</span> is usually observed within 48 hours. 
If clinical improvement of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">chronic diarrhea</span> after treatment with a maximum daily 
dose of 20 mg of diphenoxylate hydrochloride is not observed within 10 days, 
symptoms are unlikely to be controlled by further administration.</p>
<p><br></p>
<a href="#section-"></a><a href="#section-"></a>Children<p><span class="Bold">Diphenoxylate HCl and atropine sulfate is not 
recommended in children under 2 years of age and should be used with special 
caution in young children (see WARNINGS and PRECAUTIONS). The nutritional status 
and degree of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> must be considered. In children under 13 years of age, 
use oral solution. Do not use tablets for this age group.</span></p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<a href="#section-"></a>HOW SUPPLIED<p class="First">Diphenoxylate Hydrochloride and Atropine Sulfate Tablets USP are 
available as white, round tablets, debossed,</p>                                                                      <div class="Figure"><img alt="Imprint Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542b6ceb-7ad4-4d0d-b604-79bd1f567d79&amp;name=DiphAtro_imprint.jpg"></div>                                                                               <p><br></p>
<br><p>3966 containing 2.5 mg diphenoxylate hydrochloride USP and 0.025 mg 
atropine sulfate USP, packaged in bottles of 100, 1000 and unit-dose boxes of 
100 tablets.</p>
<p>PHARMACIST: Dispense in a well-closed, light-resistant container as defined 
in the USP. Use child-resistant closure.</p>
<p>Store at controlled room temperature 15°-30°C (59°-86°F) (See USP).</p>
<p>MANUFACTURED BY 0172</p>
<p>IVAX PHARMACEUTICALS, INC. 04/02</p>
<p>MIAMI, FL 33137 B9</p>
<p><br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">DIPHENOXYLATE / ATROPINE PACKAGE LABEL</span></p>
<br><p><span class="Bold">            </span><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=542b6ceb-7ad4-4d0d-b604-79bd1f567d79&amp;name=DiphAtro_label.jpg"></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIPHENOXYLATE HCL AND ATROPINE SULFATE 		
					</strong><br><span class="contentTableReg">diphenoxylate hcl and atropine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-080(NDC:0172-3966)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Diphenoxylate  Hydrochloride</strong> (Diphenoxylate) </td>
<td class="formItem">Diphenoxylate  Hydrochloride</td>
<td class="formItem">2.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Atropine Sulfate</strong> (ATROPINE) </td>
<td class="formItem">Atropine Sulfate</td>
<td class="formItem">0.025 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3966</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-080-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA086727</td>
<td class="formItem">10/29/1979</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Stat Rx USA
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Stat Rx USA</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9bfe4e61-462b-454c-a4fe-7039b969801b</div>
<div>Set id: 542b6ceb-7ad4-4d0d-b604-79bd1f567d79</div>
<div>Version: 1</div>
<div>Effective Time: 20100324</div>
</div>
</div> <div class="DistributorName">Stat Rx USA</div></p>
</body></html>
